BRPI0414860B8 - uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato - Google Patents

uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato

Info

Publication number
BRPI0414860B8
BRPI0414860B8 BRPI0414860A BRPI0414860A BRPI0414860B8 BR PI0414860 B8 BRPI0414860 B8 BR PI0414860B8 BR PI0414860 A BRPI0414860 A BR PI0414860A BR PI0414860 A BRPI0414860 A BR PI0414860A BR PI0414860 B8 BRPI0414860 B8 BR PI0414860B8
Authority
BR
Brazil
Prior art keywords
fenofibrate
composition
hypercholesterolemias
hyperlipidemias
reducing
Prior art date
Application number
BRPI0414860A
Other languages
English (en)
Inventor
Criere Bruno
Bobotas George
S Rotenberg Keith
Oury Pascal
Suplie Pascal
Chenevier Philippe
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34422141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414860(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of BRPI0414860A publication Critical patent/BRPI0414860A/pt
Publication of BRPI0414860B1 publication Critical patent/BRPI0414860B1/pt
Publication of BRPI0414860B8 publication Critical patent/BRPI0414860B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica contendo fenofibrato e método para a preparação desta. a invenção refere-se ao uso de uma composição de fenofibrato contendo fenofibrato micronizado, um tensoativo e um derivado de celulose de ligação como um adjuvante de solubilização, a referida composição contendo uma quantidade de fenofibrato maior do que ou igual a 60% em peso, para a preparação de um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que enquanto reduzindo o efeito da alimentação sobre a biodisponibilidade do fenofibrato. a invenção é da mesma forma relacionada a uma composição de liberação imediata na forma de grânulos compreendendo: (a) um núcleo neutro; (b) uma camada ativa, que cerca o núcleo; e (c) uma camada externa; em que a referida camada ativa compreende fenofibrato micronizado, um tensoativo e um derivado de celulose de ligação; e em que a referida composição tem um perfil de dissolução menor do que 10% em 5 minutos e maior do que 80% em 20 minutos de acordo com a farmacopéia européia em um meio de dissolução constituído por água com 0,025 m de lauril sulfato de sódio.
BRPI0414860A 2003-10-03 2004-10-01 uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato BRPI0414860B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/677,861 2003-10-03
US10/677,861 US7863331B2 (en) 1999-07-09 2003-10-03 Pharmaceutical composition containing fenofibrate and method for the preparation thereof
PCT/IB2004/003354 WO2005032526A1 (en) 2003-10-03 2004-10-01 Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Publications (3)

Publication Number Publication Date
BRPI0414860A BRPI0414860A (pt) 2006-11-28
BRPI0414860B1 BRPI0414860B1 (pt) 2019-01-15
BRPI0414860B8 true BRPI0414860B8 (pt) 2021-05-25

Family

ID=34422141

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414860A BRPI0414860B8 (pt) 2003-10-03 2004-10-01 uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato

Country Status (22)

Country Link
US (2) US7863331B2 (pt)
EP (2) EP1667666B9 (pt)
JP (1) JP5490354B2 (pt)
KR (1) KR101150235B1 (pt)
CN (1) CN100544712C (pt)
AT (1) ATE428408T1 (pt)
AU (1) AU2004277757B2 (pt)
BR (1) BRPI0414860B8 (pt)
CA (1) CA2540235C (pt)
CY (1) CY1109929T1 (pt)
DE (1) DE602004020641D1 (pt)
DK (1) DK1667666T3 (pt)
ES (1) ES2324670T3 (pt)
IL (1) IL174660A (pt)
MX (1) MXPA06003656A (pt)
NO (1) NO335933B1 (pt)
NZ (1) NZ546692A (pt)
PL (1) PL1667666T3 (pt)
PT (1) PT1667666E (pt)
SI (1) SI1667666T1 (pt)
WO (1) WO2005032526A1 (pt)
ZA (1) ZA200603504B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
JP2008531509A (ja) * 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
FR2940118B1 (fr) * 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010078429A1 (en) * 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
JPWO2010092925A1 (ja) * 2009-02-12 2012-08-16 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
CN101502497B (zh) * 2009-03-06 2010-11-10 安徽省药物研究所 非诺贝特药物组合物
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
EP2846778B1 (en) * 2012-05-07 2018-04-25 Bristol-Myers Squibb Holdings Ireland Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
BR112014032579A2 (pt) 2012-06-25 2017-06-27 Mylan Inc formulação de fenofibrato
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
US10278914B2 (en) 2015-08-13 2019-05-07 Coty Inc. Formulation and method for promoting cutaneous uptake of molecular oxygen by skin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
CH543472A (fr) 1969-01-31 1973-10-31 Orchimed Sa Procédé pour la préparation d'acides phénoxyalcoyl-carboxyliques
GB1579818A (en) 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0012523B2 (en) 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2494112B1 (pt) 1980-11-19 1986-01-10 Laruelle Claude
GB8414221D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
WO1992000064A1 (de) 1990-07-02 1992-01-09 Boehringer Mannheim Gmbh Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5223268A (en) 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DE69127275T2 (de) 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5480330A (en) * 1994-10-04 1996-01-02 Outboard Marine Corporation Marine propulsion pump with two counter rotating impellers
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
DE19608750A1 (de) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
CA2258683C (en) 1996-06-28 2007-07-31 Schering Corporation Oral composition comprising a triazole antifungal compound
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
AU2005299A (en) * 1997-12-20 1999-07-12 Genencor International, Inc. Fluidized bed matrix granule
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
JP2001089373A (ja) * 1999-09-24 2001-04-03 Tanabe Seiyaku Co Ltd 経口投与製剤
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US8026281B2 (en) 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
ATE398878T1 (de) * 2006-04-20 2008-07-15 Alcatel Lucent Verfahren und vorrichtung für effiziente gewichtete und gerechte datenüberwachung

Also Published As

Publication number Publication date
CN1863518A (zh) 2006-11-15
ATE428408T1 (de) 2009-05-15
HK1084895A1 (en) 2006-08-11
ES2324670T3 (es) 2009-08-12
EP2000133A2 (en) 2008-12-10
CA2540235A1 (en) 2005-04-14
AU2004277757A1 (en) 2005-04-14
KR101150235B1 (ko) 2012-07-05
ZA200603504B (en) 2007-04-25
DK1667666T3 (da) 2009-06-22
JP5490354B2 (ja) 2014-05-14
EP1667666B1 (en) 2009-04-15
US20100112049A1 (en) 2010-05-06
WO2005032526A1 (en) 2005-04-14
JP2007507486A (ja) 2007-03-29
US7863331B2 (en) 2011-01-04
NO335933B1 (no) 2015-03-30
US8529952B2 (en) 2013-09-10
EP1667666B9 (en) 2009-10-21
CY1109929T1 (el) 2014-09-10
AU2004277757B2 (en) 2010-03-04
US20040137055A1 (en) 2004-07-15
SI1667666T1 (sl) 2009-08-31
PT1667666E (pt) 2009-06-15
CA2540235C (en) 2012-07-17
BRPI0414860A (pt) 2006-11-28
EP2000133A3 (en) 2009-05-13
BRPI0414860B1 (pt) 2019-01-15
NZ546692A (en) 2010-03-26
NO20061960L (no) 2006-05-03
IL174660A0 (en) 2006-08-20
DE602004020641D1 (de) 2009-05-28
IL174660A (en) 2011-10-31
EP1667666A1 (en) 2006-06-14
CN100544712C (zh) 2009-09-30
KR20060123728A (ko) 2006-12-04
PL1667666T3 (pl) 2009-09-30
MXPA06003656A (es) 2006-06-05

Similar Documents

Publication Publication Date Title
BRPI0414860B8 (pt) uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato
CA1319605C (en) Virucidal agent having wide-spectrum activity
BR0114392A (pt) Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
HRP20120136T1 (hr) Imunogeni pripravak koji sadrži adjuvans
BR0116945A (pt) Uma preparação para prevenção de restenose
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR018673A1 (es) Derivados de 1,3-oxazolina y 1,3-tiazolina; procedimiento para su preparacion, composicion fitoprotectora, fungicida, insecticida acaricida nematocida y para la aplicacion en la proteccion de la madera o como agente de conservacion en masas de ...
BRPI0804518A2 (pt) método de controle de uma população de cães
EA021762B1 (ru) Применение способной к вспениванию композиции, по существу, не содержащей фармацевтически активные ингредиенты, для лечения кожи человека
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
BR0017268A (pt) Composição farmacêutica de propofol, aquosa, lìmpida, estável na esterilização em autoclave, apropriada para administração parenteral, e processo para a preparação de uma composição farmacêutica de propofol, aquosa, lìmpida, estável na esterilização em autoclave, apropriada para administração parenteral
BR0307494A (pt) Composição que contêm extrato de palha de aveia e de erva de salgueiro
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
BRPI0407667A (pt) metabólitos de estradiol para o tratamento de hipertensão pulmonar
BRPI0413474A (pt) uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BR0210063A (pt) Composição estável e uso da mesma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/50, A61K 31/216, A61P 3/00

Ipc: A61K 9/50 (2011.01), A61K 31/216 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2847 DE 29-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.